Search results
Showing 76 to 90 of 105 results for bladder cancer
This advice has been updated and replaced by NICE healthtech guidance 601.
We have moved Medical technologies guidance 61 to become HealthTech guidance 601. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
This guideline covers the clinical care of adults (18 years and over) who are dying during the last 2 to 3 days of life. It aims to improve end of life care for people in their last days of life by communicating respectfully and involving them, and the people important to them, in decisions and by maintaining their comfort and dignity. The guideline covers how to manage common symptoms without causing unacceptable side effects and maintain hydration in the last days of life.
Axonics sacral neuromodulation system for treating refractory overactive bladder (HTG554)
Evidence-based recommendations on Axonics sacral neuromodulation system for treating refractory overactive bladder.
Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia (HTG545)
Evidence-based recommendations on Rezum for treating lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Electrically-stimulated intravesical chemotherapy for superficial bladder cancer (IPG277)
Interventional procedures, IPG277 - Issued: November 2008 --> This guidance has been updated and replaced by NICE interventional procedures guidance 638.
This guideline covers care and support for adults with cerebral palsy. It aims to improve health and wellbeing, promote access to services and support participation and independent living.
This guideline covers care and treatment for adults (aged 18 and over) with type 1 diabetes. It includes advice on diagnosis, education and support, blood glucose management, cardiovascular risk, and identifying and managing long-term complications.
Evidence-based recommendations on avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy in adults.
Interventional procedures, IPG235 - Issued: October 2007 --> This guidance has been updated and replaced by NICE interventional procedures guidance 628.
Electrically stimulated intravesical chemotherapy for non-muscle-invasive bladder cancer (IPG638)
We have moved interventional procedures guidance 638 to become HealthTech guidance 499. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Transurethral laser ablation for recurrent non-muscle-invasive bladder cancer (IPG656)
We have moved interventional procedures guidance 656 to become HealthTech guidance 522. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer [ID1169]
Discontinued Reference number: GID-TA10324
Intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer (IPG628)
We have moved interventional procedures guidance 628 to become HealthTech guidance 487. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer [ID1335]
Discontinued Reference number: GID-TA10315